Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196362802> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3196362802 abstract "Abstract Background Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its superior efficacy vs. placebo. Methods The budget impact analysis at hand is focused on patients at high risk of CDI recurrence. Treatment with standard of care (SoC) + bezlotoxumab was compared with current SoC alone in the 10 most associated Diagnosis Related Groups to identify, analyze, and evaluate potential cost savings per case from the German hospital management perspective. Based on variation in days to rehospitalization, three different case consolidation scenarios were assessed: no case consolidation, case consolidation for the SoC + bezlotoxumab treatment arm only, and case consolidation for both treatment arms. Results On average, the budget impact amounted to € 508.56 [range: € 424.85 - € 642.19] for no case consolidation, € 470.50 [range: € 378.75 - € 601.77] for case consolidation in the SoC + bezlotoxumab treatment arm, and € 618.00 [range: € 557.40 - € 758.41] for case consolidation in both treatment arms. Conclusions The study demonstrated administration of SoC + bezlotoxumab in patients at high risk of CDI recurrence is cost-saving from a hospital management perspective. Reduced length of stay in bezlotoxumab treated patients creates free spatial and personnel capacities for the treating hospital. Yet, a requirement for hospitals to administer bezlotoxumab is the previously made request for additional fees and a successful price negotiation." @default.
- W3196362802 created "2021-09-13" @default.
- W3196362802 creator A5004842966 @default.
- W3196362802 creator A5026731919 @default.
- W3196362802 creator A5027312193 @default.
- W3196362802 creator A5050760229 @default.
- W3196362802 creator A5055554326 @default.
- W3196362802 creator A5084457251 @default.
- W3196362802 date "2021-09-09" @default.
- W3196362802 modified "2023-10-13" @default.
- W3196362802 title "A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany" @default.
- W3196362802 cites W1916481354 @default.
- W3196362802 cites W1969144992 @default.
- W3196362802 cites W2078383435 @default.
- W3196362802 cites W2080394999 @default.
- W3196362802 cites W2111990189 @default.
- W3196362802 cites W2582069104 @default.
- W3196362802 cites W2743613745 @default.
- W3196362802 cites W2766283594 @default.
- W3196362802 cites W2790379948 @default.
- W3196362802 cites W2791326569 @default.
- W3196362802 cites W2810811277 @default.
- W3196362802 cites W2897125298 @default.
- W3196362802 cites W2904608360 @default.
- W3196362802 cites W3092596392 @default.
- W3196362802 cites W853874020 @default.
- W3196362802 doi "https://doi.org/10.1186/s12913-021-06970-8" @default.
- W3196362802 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8428130" @default.
- W3196362802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34496836" @default.
- W3196362802 hasPublicationYear "2021" @default.
- W3196362802 type Work @default.
- W3196362802 sameAs 3196362802 @default.
- W3196362802 citedByCount "3" @default.
- W3196362802 countsByYear W31963628022023 @default.
- W3196362802 crossrefType "journal-article" @default.
- W3196362802 hasAuthorship W3196362802A5004842966 @default.
- W3196362802 hasAuthorship W3196362802A5026731919 @default.
- W3196362802 hasAuthorship W3196362802A5027312193 @default.
- W3196362802 hasAuthorship W3196362802A5050760229 @default.
- W3196362802 hasAuthorship W3196362802A5055554326 @default.
- W3196362802 hasAuthorship W3196362802A5084457251 @default.
- W3196362802 hasBestOaLocation W31963628021 @default.
- W3196362802 hasConcept C121955636 @default.
- W3196362802 hasConcept C144133560 @default.
- W3196362802 hasConcept C194828623 @default.
- W3196362802 hasConcept C2776014549 @default.
- W3196362802 hasConcept C71924100 @default.
- W3196362802 hasConceptScore W3196362802C121955636 @default.
- W3196362802 hasConceptScore W3196362802C144133560 @default.
- W3196362802 hasConceptScore W3196362802C194828623 @default.
- W3196362802 hasConceptScore W3196362802C2776014549 @default.
- W3196362802 hasConceptScore W3196362802C71924100 @default.
- W3196362802 hasFunder F4320327730 @default.
- W3196362802 hasIssue "1" @default.
- W3196362802 hasLocation W31963628021 @default.
- W3196362802 hasLocation W31963628022 @default.
- W3196362802 hasLocation W31963628023 @default.
- W3196362802 hasOpenAccess W3196362802 @default.
- W3196362802 hasPrimaryLocation W31963628021 @default.
- W3196362802 hasRelatedWork W159247329 @default.
- W3196362802 hasRelatedWork W2025193597 @default.
- W3196362802 hasRelatedWork W2026095104 @default.
- W3196362802 hasRelatedWork W2042489430 @default.
- W3196362802 hasRelatedWork W2083479052 @default.
- W3196362802 hasRelatedWork W2115778339 @default.
- W3196362802 hasRelatedWork W2626766173 @default.
- W3196362802 hasRelatedWork W2748952813 @default.
- W3196362802 hasRelatedWork W2899084033 @default.
- W3196362802 hasRelatedWork W3031052312 @default.
- W3196362802 hasVolume "21" @default.
- W3196362802 isParatext "false" @default.
- W3196362802 isRetracted "false" @default.
- W3196362802 magId "3196362802" @default.
- W3196362802 workType "article" @default.